83 FR 55904 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 217 (November 8, 2018)

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

[Federal Register Volume 83, Number 217 (Thursday, November 8, 2018)]
[Notices]
[Pages 55904-55905]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-24468]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Dr. Jenish Patel, Ph.D., 240-669-2894; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Universal Influenza Virus Probes for Enrichment of Influenza Viral 
Sequences

    Description of Technology:
    This technology is a set of influenza virus enrichment probes 
developed to increase the sensitivity of sequence-based, universal 
detection of all influenza viruses. This universal influenza enrichment 
probe set contains a unique set of 46,953 biotin-labeled, RNA probes, 
each 120 base-pairs long, that can be used to enrich for any influenza 
sequences without prior knowledge of type or subtype. This probe set 
can capture and enrich influenza viral sequences selectively and 
effectively in a variety of samples, such as clinical samples with 
degraded nucleotides or samples containing very low amounts of 
influenza virus, thus making it a valuable tool for influenza virus 
diagnoses and surveillance.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Influenza diagnostics; influenza surveillance
    Competitive Advantages:
     Highly sensitive detection of influenza viruses
     Detection of any influenza viruses in a variety of samples
    Development Stage:
     In vitro Testing
    Inventors: Yongli Xiao, Ph.D., (NIAID), Jeffrey Taubenberger, 
Ph.D., (NIAID), and Zong-Mei Sheng, Ph.D. (NIAID)
    Publications: Xiao Y, et al. Design and validation of a universal 
influenza virus enrichment probe set and its utility in deep sequence 
analysis of primary cloacal swab surveillance samples of wild birds. 
Virology, 2018, Nov; 524:182-191 [PMID 30212665]
    Intellectual Property: HHS Reference No. E-032-2018/0--US-01 Patent 
Application No. 62/611,734 filed December 29, 2017.
    Licensing Contact: Jenish Patel, Ph.D., 240-669-2894; 
[email protected]
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases (NIAID) is also

[[Page 55905]]

seeking statements of capability or interest from parties interested in 
collaborative research, such as from bio-analytic research groups to 
develop rapid influenza monitoring, diagnostic, and surveillance 
devices and biotechnology companies to formulate and test influenza 
next generation sequencing kits for challenging influenza infected 
samples, for example zoonotic infections of influenza A virus subtypes 
differing from currently circulating human influenza viruses or in 
mixed infections. NIAID will consider executing a Confidentiality 
Agreement with a prospective collaborator to facilitate receipt of a 
Capability Statement if requested. For collaboration opportunities, 
please contact Jenish Patel, Ph.D., 240-669-2894; [email protected].

    Dated: October 19, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-24468 Filed 11-7-18; 8:45 am]
 BILLING CODE 4140-01-P